Efficacy of first-line treatment options in advanced HER2-altered non-small cell lung cancer: A multi-center retrospective study

被引：0
|
作者：
Sun, H. [1 ,2 ]
Ge, Y. [1 ]
Wu, J. [1 ]
Sun, Y. [1 ]
Zhang, J. [1 ]
Cheng, Q. [1 ]
Wang, D. [1 ]
Wang, X. [1 ]
Li, J. [1 ]
Fu, X. [2 ]
Sun, H. [1 ,2 ]
Gao, A. [2 ]
机构：
[1] Shandong First Med Univ, Phase Clin Res Ctr 1, Canc Hosp, Jinan, Peoples R China
[2] Shandong First Med Univ, Dept Thorac Radiat Oncol, Canc Hosp, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2420
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1387P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pemetrexed in first-line treatment of non-small cell lung cancer
    Esteban, Emilio
    Casillas, Marta
    Cassinello, Alejo
    CANCER TREATMENT REVIEWS, 2009, 35 (04) : 364 - 373
  • [22] The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    CANCERS, 2023, 15 (08)
  • [23] Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Fleeman, N.
    Bagust, A.
    McLeod, C.
    Greenhalgh, J.
    Boland, A.
    Dundar, Y.
    Dickson, R.
    Smith, C. Tudur
    Davis, H.
    Green, J.
    Pearson, M.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
  • [24] Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Brown, T.
    Boland, A.
    Bagust, A.
    Oyee, J.
    Hockenhull, J.
    Dundar, Y.
    Dickson, R.
    Ramani, V. S.
    Proudlove, C.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 71 - 79
  • [25] Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    Jahan, N.
    Swarup, S.
    Sultan, A.
    Naing, T.
    Mogollon-Duffo, F.
    Ball, S.
    Tun, A.
    Htut, T.
    Dash, A.
    D'Cunha, N.
    Hardwicke, F.
    Awasthi, S.
    Tijani, L.
    Thein, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S917 - S918
  • [26] BIWEEKLY CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER
    Benekli, Mustafa
    Gunaydin, Yusuf
    Inanc, Mevlude
    Ozkan, Metin
    Demirci, Ayse
    Demirci, Umut
    Suner, Ali
    Karaca, Halit
    Tonyali, Onder
    Berk, Veli
    Buyukberber, Suleyman
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S563 - S563
  • [27] Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study
    Ni Jun
    Wang Hanping
    Si Xiaoyan
    Xu Yan
    Wang Mengzhao
    Zhang Xiaotong
    Zhang Li
    THORACIC CANCER, 2020, 11 (07) : 1869 - 1875
  • [28] CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
    Kang, Liping
    Mai, Jianliang
    Liang, Weiting
    Zou, Qihua
    Huang, Caiwen
    Lin, Yongbin
    Liang, Ying
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Carboplatin and Gemcitabine in First-Line Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer: Data from a Retrospective Study
    Genestreti, G.
    Giovannini, N.
    Frizziero, M.
    Maglie, M.
    Sanna, S.
    Cingarlini, S.
    Molino, A. M.
    Piciucchi, S.
    Cetto, G. L.
    Santo, A.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (04) : 232 - 237
  • [30] A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer.
    Giaccone, G
    Lechevalier, T
    Thatcher, N
    Smit, E
    Janmaat, M
    Rodriguez, J
    Oulid-Aissa, D
    Soria, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 638S - 638S
12345